Sony Corporation and Astellas Pharma Inc. announced that they have entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate platform in oncology based on Sony’s unique polymeric material, “KIRAVIA™ Backbone.”
Sony Corporation and Astellas Pharma Inc. announced that they have entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate platform in oncology based on Sony’s unique polymeric material, “KIRAVIA™ Backbone.”